The U.S. Food and Drug Administration (FDA) has just approved a drug called Darzalex (daratumumab) in combination with the drug Velcade (bortezomib), melphalan, and prednisone (known collectively as VMP) for patients who have been recently diagnosed with multiple myeloma but are not eligible for autologous stem cell transplant, reports CNBC.
Multiple myeloma, also known as bone marrow cancer, is a form of cancer that can affect many areas of the body, including the spine, pelvis, skull, and ribs. It affects the bones and blood cell production. People with multiple myeloma often experience tiredness, aches and pains, frequent infection, and weak bones, among other symptoms. Unfortunately, most of the patients that are diagnosed will not be cured. Patients are often given drugs to control and prevent relapses of cancer and to counteract its symptoms. Research into this area is on-going.